期刊文献+

二膦酸盐相关颌骨骨坏死 被引量:1

原文传递
导出
摘要 二膦酸盐具有很强的抗骨质吸收的作用,20世纪70年代开始应用于临床,已被证实对于良、恶性骨病有效,包括骨质疏松症、Paget病,一些代谢性骨病以及因乳腺癌、肺癌、前列腺癌所致骨转移及多发性骨髓瘤。二膦酸盐的作用主要是抑制破骨细胞,引起破骨细胞的凋亡。用于癌症患者可以防止骨骼并发症,减少骨痛,并且提高生存质量。
出处 《中华口腔医学杂志》 CAS CSCD 北大核心 2007年第8期510-512,共3页 Chinese Journal of Stomatology
  • 相关文献

参考文献19

  • 1Licata AA. Discovery, clinical development, and therapeutic uses of bisphosphonates. Ann Pharmacother, 2005, 39(4): 668-677.
  • 2Russell RG. Bisphosphonates From Bench to Bedside. Ann N Y Acad Sci, 2006, 1068: 367-401.
  • 3Marx RE. Pamidronate ( Aredia ) and zoledronate ( Zometa ) induced avascular necrosis of the jaws : a growing epidemic. J Oral Maxillofac Surg, 2003, 61(9) :1115-1117.
  • 4Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates . N Engl J Med, 2005,353( 1 ) :99-102.
  • 5Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol ,2005,23(34) :8580-8587.
  • 6Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol ,2006, 24(6): 945-952.
  • 7Maerevoet M, Martin C, Duck L. Osteonecrosis of the jaw and bisphosphonates. New Engl J Med, 2005 ,353 ( 1 ) :100-101.
  • 8Migliorati CA, Casiglia J, Epstein J, et al. Managing the care of patients with bisphosphonate-associated osteonecrosis : an American Academy of Oral Medicine position paper. J Am Dent Assoc, 2005, 136(12) : 1658-1668.
  • 9Migliorati CA, Schubert MM, Peterson DE, et al. Bisphosphonate associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer, 2005,104( 1 ) :83-93.
  • 10Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg,2005, 63 ( 11 ) :1567-1575.

同被引文献17

  • 1Sawatari Y, Marx RE. Bisphosphonates and bisphosphonate induced osteonecrosis. Oral Maxillofac Surg Clin North Am,2007, 19(4) :487-498.
  • 2Maerevoet M, Martin C, Duck L. Osteoneerosis of the jaw and bisphosphonates. N Engl J Med,2005,353( 1 ) :99-102.
  • 3Reid IR. Bisphosphonates. Skeletal Radiol, 2007,36 (8) : 711-714.
  • 4Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer, 2000, 88 ( 12 Suppl) :2961-2978.
  • 5Rodan GA,Reszka AA. Bisphosphonate meehanism of action. CmT Mol Med ,2002,2 ( 6 ) :571-577.
  • 6Lambrinoudaki I, Christodoulakos G, Botsis D. Bisphosphonates. Ann N Y Acad Sci,2006,1092:397-402.
  • 7Marx RE. Pamidronatc ( Aredia ) and zoledronate ( Zometa ) induced avaseular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg ,2003,61 ( 9 ) : 1115-1117.
  • 8Mawardi H, Giro G, Kajiya M, et al. A role of oral baeteria in bisphosphonate-indueed osteoneerosis of the jaw. J Dent Res, 2011,90( 11 ) :1339-1345.
  • 9Seth R, Futran ND, Alam DS, et al. Outcomes of vascularized bone graft reconstruction of the mandible in bisphosphonate-related osteonecrosis of the jaws. Laryngoscope, 2010, 120 ( 11 ): 2165-2171.
  • 10Moretti F, Pelliccioni GA, Montebugnoli L, et al. A prospective clinical trial for assessing the efficacy of a minimally invasive protocol in patients with bisphosphonate-assoeiated osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2011,112(6) :777-782.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部